0000899243-23-009182.txt : 20230320
0000899243-23-009182.hdr.sgml : 20230320
20230320203101
ACCESSION NUMBER: 0000899243-23-009182
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230316
FILED AS OF DATE: 20230320
DATE AS OF CHANGE: 20230320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klee Justin B.
CENTRAL INDEX KEY: 0001898314
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 23747649
MAIL ADDRESS:
STREET 1: C/O AMYLYX PHARMACEUTICALS, INC.
STREET 2: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-16
0
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001898314
Klee Justin B.
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
1
1
0
0
Co-Chief Executive Officer
0
Common Stock
2023-03-16
4
S
0
96555
31.8405
D
2796062
D
Common Stock
2023-03-16
4
S
0
3445
32.4751
D
2792617
D
Common Stock
2023-03-16
4
A
0
50000
0.00
A
2842617
D
Stock Option (right to buy)
32.08
2023-03-16
4
A
0
225000
0.00
A
2033-03-16
Common Stock
225000
225000
D
These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.32 to $32.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
/s/ Joshua B. Cohen, as Attorney in Fact
2023-03-20